Leverkusen, April 27, 2017 – The Supervisory Board of Bayer AG has extended the current service contract of Chief Financial Officer Johannes Dietsch (55) until May 31, 2018. After that date, Johannes Dietsch will be leaving the company at his own request. “Designing the detailed financing of the Monsanto acquisition and the ongoing approval and […]
Monheim, April 24, 2017 – Bayer announces the establishment of a partnership with Goodbye Malaria. Both organizations will jointly support the objectives of Ending Malaria for Good in Southern Africa. The figures published in the 2016 WHO malaria report, with malaria cases falling by 21 percent between 2010 and 2015 and malaria death rates falling […]
Transaction formally closed in the first quarter of 2016 / Laboratory and office space will be near Kendall Square in Cambridge, MA / Hiring is underway and efforts have begun on initial programs in hematology and ophthalmology Leverkusen, Germany and Basel, Switzerland, August 19, 2016 – Casebia Therapeutics, the joint venture founded by Bayer and […]
The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology / Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit / The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from CRISPR Therapeutics as well […]
Dr. Abigail Doyle (Associate Professor at Princeton University, USA) wins the „Chemistry“ category / Dr. Steven Spoel (Principal Investigator at the University of Edinburgh, UK) takes the „Biology“ award /Dr. Javier Fernandez (Associate Researcher at Wyss Institute/Harvard University, Boston, USA) awarded prize in the „Materials“ field Leverkusen, January 10, 2013 – The winners of the Bayer […]
Special global web conference “One Health” to address zoonotic disease within the veterinary and public health fields Leverkusen, January 9, 2014 – Nearly half of the world’s population is infected with at least one type of vector-borne disease (1). These diseases are transmitted from parasites to animals and humans, and have a significant impact on public health […]
TARRYTOWN, N.Y., Dec. 18, 2013 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company’s supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA […]